# MOS

## Overview
The MOS gene encodes the MOS proto-oncogene, a serine/threonine kinase that plays a pivotal role in cell cycle regulation, particularly during meiosis. This kinase is integral to the maturation of oocytes, where it activates and stabilizes the maturation-promoting factor (MPF), ensuring proper chromosomal alignment and segregation. MOS is a key component of the cytostatic factor (CSF), maintaining metaphase II arrest in vertebrate eggs until fertilization occurs. Functioning through the mitogen-activated protein (MAP) kinase pathway, MOS phosphorylates MAP kinase kinase (MAPKK), leading to the activation of MAP kinase, which is crucial for germinal vesicle breakdown and meiotic spindle assembly. Beyond its physiological roles, alterations in MOS expression have been implicated in oncogenic processes, including lung cancer and acute myeloblastic leukemia, highlighting its significance in both normal cellular function and disease (Yew1993Mos; Diaz1985The; Athanasiou2000c‐mos; Singh1997Mos).

## Structure
The MOS proto-oncogene encodes a serine/threonine kinase with a molecular structure that includes a catalytic core similar to that of protein kinase A (PKA). The primary structure of MOS consists of a sequence of amino acids, with a notable proline-rich region at the N-terminus that is excluded from structural alignment due to its unlikely formation of an extended α helix (Robertson1996Identification). The secondary structure of MOS includes conserved elements such as α helices and β sheets, with a unique 12-residue insertion between the β9 strand and αF helix compared to PKA (Robertson1996Identification).

The tertiary structure of MOS is characterized by a bilobal conformation, with the active site located at the junction of the two lobes. The small lobe is associated with nucleotide binding, while the large lobe is involved in peptide binding and catalysis (Robertson1996Identification). A distinctive feature of MOS is its autoinhibitory loop, spanning residues A-221 to H-232, which is hypothesized to block substrate access to the active site, acting as an autoinhibitory domain (Robertson1996Identification).

Post-translational modifications, such as phosphorylation, play a crucial role in regulating MOS activity. Phosphorylation at specific serine residues, including Ser-3, is important for stabilizing the protein and facilitating interactions with mitogen-activated protein kinase kinase (MKK) (Chen1995Ser3).

## Function
The MOS proto-oncogene encodes a serine/threonine kinase that plays a critical role in the regulation of the meiotic cell cycle, particularly in oocyte maturation. MOS is essential for the activation and stabilization of the maturation-promoting factor (MPF), a key regulator of meiosis and mitosis, ensuring proper chromosomal alignment and segregation during meiosis I and II (Yew1993Mos; Singh1997Mos). It is a component of the cytostatic factor (CSF), which maintains metaphase II arrest in vertebrate eggs, preventing premature progression to anaphase until fertilization occurs (Singh1997Mos; de1998Mutation).

MOS functions through the activation of the mitogen-activated protein (MAP) kinase pathway, where it phosphorylates MAP kinase kinase (MAPKK), leading to the activation of MAP kinase, which is crucial for processes such as germinal vesicle breakdown (GVBD) and meiotic spindle assembly (Posada1993Mos; Singh1997Mos). In human eggs, MOS is involved in maintaining high MPF activity during meiosis, particularly in the transition from meiosis I to meiosis II, by inhibiting the degradation of cyclin B (Pal1994Expression). This regulatory role is vital for normal oocyte development and fertility.

## Clinical Significance
Alterations in the expression of the MOS gene, which encodes a serine/threonine kinase, have been implicated in various oncogenic processes. In lung cancer, particularly non-small cell lung carcinomas (NSCLCs), c-mos expression is associated with better recurrence-free survival, suggesting a potential role in prognosis (Athanasiou2000c‐mos). However, the overexpression of MOS can lead to genetic instability by inducing meiotic-like alterations in the mitotic spindle, contributing to tumor development (Athanasiou2000c‐mos).

In the context of cellular transformation, the Mos/MAPK pathway is known to interact with the p53 gene. In p53-deficient cells, MOS overexpression results in genomic instability, characterized by abnormal mitotic spindles and centrosome amplification, which are key features in cancer development (Fukasawa1997Synergy). The loss of p53 function, combined with Mos/MAPK activation, enhances aneuploidy and chromosomal instability (Fukasawa1997Synergy).

The MOS gene has also been studied in the context of acute myeloblastic leukemia (AML), where it is involved in the 8;21 chromosomal translocation. This translocation suggests a potential role for MOS in the development of AML, although it has not been associated with spontaneously developing malignancies in other contexts (Diaz1985The).

## Interactions
The MOS proto-oncogene, a serine/threonine kinase, is involved in several critical protein interactions that regulate its function in cell cycle processes. MOS interacts with the molecular chaperone Hsp70, forming complexes that are crucial for maintaining its kinase activity. This interaction is mediated by the phosphorylation of the MOS residue Serine 3, which is essential for the stability and activity of MOS (Liu1999Evidence). 

MOS also interacts with mitogen-activated protein kinase kinase (MKK), a key component of the MAPK signaling pathway. This interaction requires either MOS kinase activity or a negative charge at the Ser-3 autophosphorylation site, which is crucial for the activation of MKK and subsequent MAPK activation (Chen1995Ser3). 

Additionally, MOS forms a complex with Hsp90, another molecular chaperone. Hsp90 is necessary for MOS activation, and its inhibition disrupts MOS function. The interaction with Hsp90 is transient and does not depend on MOS's kinase activity (Fisher2000Hsp90). 

MOS is also regulated by the β subunit of casein kinase II (CKIIβ), which binds to MOS and inhibits its activity, affecting MOS-mediated MAPK activation (Chen1997The).


## References


[1. (Chen1995Ser3) Mingzi Chen and Jonathan A. Cooper. Ser-3 is important for regulating mos interaction with and stimulation of mitogen-activated protein kinase kinase. Molecular and Cellular Biology, 15(9):4727–4734, September 1995. URL: http://dx.doi.org/10.1128/mcb.15.9.4727, doi:10.1128/mcb.15.9.4727. This article has 22 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.15.9.4727)

[2. (Yew1993Mos) Nelson Yew, Marjorie Strobel, and George F. Vande Woude. Mos and the cell cycle: the molecular basis of the transformed phenotype. Current Opinion in Genetics &amp; Development, 3(1):19–25, February 1993. URL: http://dx.doi.org/10.1016/s0959-437x(05)80336-3, doi:10.1016/s0959-437x(05)80336-3. This article has 46 citations.](https://doi.org/10.1016/s0959-437x(05)80336-3)

[3. (Diaz1985The) Manuel O. Diaz, Michelle M. Le Beau, Janet D. Rowley, Harry A. Drabkin, and David Patterson. The role of the c- mos gene in the 8;21 translocation in human acute myeloblastic leukemia. Science, 229(4715):767–769, August 1985. URL: http://dx.doi.org/10.1126/science.3860954, doi:10.1126/science.3860954. This article has 40 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.3860954)

[4. (Athanasiou2000c‐mos) A Athanasiou, V G Gorgoulis, P Zacharatos, G Mariatos, A Kotsinas, T Liloglou, A Karameris, P Foukas, E N Manolis, J K Field, and C Kittas. C‐mos immunoreactivity is an indicator of good prognosis in lung cancer. Histopathology, 37(1):45–54, July 2000. URL: http://dx.doi.org/10.1046/j.1365-2559.2000.00898.x, doi:10.1046/j.1365-2559.2000.00898.x. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1046/j.1365-2559.2000.00898.x)

[5. (Singh1997Mos) Balraj Singh and Ralph B. Arlinghaus. Mos and the cell cycle, pages 251–259. Springer US, 1997. URL: http://dx.doi.org/10.1007/978-1-4615-5371-7_20, doi:10.1007/978-1-4615-5371-7_20. This article has 19 citations.](https://doi.org/10.1007/978-1-4615-5371-7_20)

[6. (de1998Mutation) KAF de Foy, SA Gayther, WH Colledge, S Crockett, IV Scott, MJ Evans, and BAJ Ponder. Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas. British Journal of Cancer, 77(10):1642–1644, May 1998. URL: http://dx.doi.org/10.1038/bjc.1998.269, doi:10.1038/bjc.1998.269. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.1998.269)

[7. (Posada1993Mos) James Posada, Nelson Yew, Natalie G. Ahn, George F. Vande Woude, and Jonathan A. Cooper. Mos stimulates map kinase in xenopus oocytes and activates a map kinase kinase in vitro. Molecular and Cellular Biology, 13(4):2546–2553, April 1993. URL: http://dx.doi.org/10.1128/mcb.13.4.2546-2553.1993, doi:10.1128/mcb.13.4.2546-2553.1993. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.13.4.2546-2553.1993)

[8. (Fukasawa1997Synergy) Kenji Fukasawa and George F. Vande Woude. Synergy between the mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Molecular and Cellular Biology, 17(1):506–518, January 1997. URL: http://dx.doi.org/10.1128/mcb.17.1.506, doi:10.1128/mcb.17.1.506. This article has 91 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.17.1.506)

[9. (Fisher2000Hsp90) D.L. Fisher. Hsp90 is required for c-mos activation and biphasic map kinase activation in xenopus oocytes. The EMBO Journal, 19(7):1516–1524, April 2000. URL: http://dx.doi.org/10.1093/emboj/19.7.1516, doi:10.1093/emboj/19.7.1516. This article has 54 citations.](https://doi.org/10.1093/emboj/19.7.1516)

[10. (Liu1999Evidence) Hui Liu, Vijayalakshmi B Vuyyuru, Chau D Pham, Yandan Yang, and Balraj Singh. Evidence of an interaction between mos and hsp70: a role of the mos residue serine 3 in mediating hsp70 association. Oncogene, 18(23):3461–3470, June 1999. URL: http://dx.doi.org/10.1038/sj.onc.1202699, doi:10.1038/sj.onc.1202699. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1202699)

[11. (Robertson1996Identification) Scott C. Robertson and Daniel J. Donoghue. Identification of an autoinhibitory region in the activation loop of the mos protein kinase. Molecular and Cellular Biology, 16(7):3472–3479, July 1996. URL: http://dx.doi.org/10.1128/mcb.16.7.3472, doi:10.1128/mcb.16.7.3472. This article has 3 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.16.7.3472)

[12. (Chen1997The) Mingzi Chen, Dongxia Li, Edwin G. Krebs, and Jonathan A. Cooper. The casein kinase ii β subunit binds to mos and inhibits mos activity. Molecular and Cellular Biology, 17(4):1904–1912, April 1997. URL: http://dx.doi.org/10.1128/mcb.17.4.1904, doi:10.1128/mcb.17.4.1904. This article has 83 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.17.4.1904)

[13. (Pal1994Expression) Subrata K. Pal, Donald Torry, Ricardo Serta, Richard C. Crowell, Machelle M. Seibel, Geoffrey M. Cooper, and Ann A. Kiessling. Expression and potential function of the c-mos proto-oncogene in human eggs. Fertility and Sterility, 61(3):496–503, March 1994. URL: http://dx.doi.org/10.1016/s0015-0282(16)56582-0, doi:10.1016/s0015-0282(16)56582-0. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0015-0282(16)56582-0)